American Society of Clinical Oncology (ASCO)

The American Society of Clinical Oncology (ASCO) is a professional organization representing physicians of all oncology sub-specialties who care for people with cancer. Founded in 1964 by Fred Ansfield, Harry Bisel, Herman Freckman, Arnoldus Goudsmit, Robert Talley, William Wilson, and Jane C. Wright, it has nearly 45,000 members worldwide.

Antitumor Activity of Selpercatinib (LOXO-292) in Patients with RET-Mutant Medullary Thyroid Cancer

ASCO 2020 – Wrap Up

Selpercatinib (LOXO-292) use was associated with durable antitumor activity in patients with RET-mutant medullary thyroid cancer previously treated with cabozantinib and/or vandetanib as well as in cabozantinib/vandetanib-naïve patients. Read More ›

Liquid Biopsy Compared with Tissue Biopsy for Molecular Profiling in Patients with NSCLC

ASCO 2020 – Wrap Up

In newly diagnosed patients with lung cancer, liquid biopsy using the Guardant 360 assay identifies actionable targets beyond those identified by tumor tissue profiling alone and with a shorter turnaround time. Read More ›

Efficacy of Amivantamab (JNJ-61186372) in Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutation

ASCO 2020 – Wrap Up

Results from the CHRYSALIS study show that amivantamab demonstrates robust and durable antitumor activity and a manageable safety profile in patients with EGFR exon20ins-mutated non–small-cell lung cancer. Read More ›

Barriers to Targeted Therapies for NSCLC Patients with Highly Actionable Gene Variants in the Veterans Health Affairs Program

ASCO 2020 – Wrap Up

A substantial minority of patients with advanced non–small-cell lung cancer and highly actionable gene variants were not prescribed available targeted therapies in the Veterans Health Affairs National Precision Oncology Program. Read More ›

ADAURA Results: Osimertinib as Adjuvant Therapy for EGFR-Mutated NSCLC

ASCO 2020 – Lung Cancer

Approximately 30% of patients with non–small-cell lung cancer present with early-stage (I-IIIA) disease and undergo surgery. Researchers assessed the use of adjuvant osimertinib in this population. Read More ›

Patterns of Acquired Resistance in Patients with NSCLC Who Receive PD-1 Inhibitors

ASCO 2020 – Lung Cancer

The frequency and durability of outcomes associated with acquired resistance to PD-1 inhibition in non–small-cell lung cancer are presented. Read More ›

Characteristics of Patients Who Achieve Long-Term Response with PD-1 Blockade

ASCO 2020 – Lung Cancer

The characteristics of long-term responders to PD-1 blockade are presented. Read More ›

Smoking Cessation and Lung Cancer: Recent Quitters Benefit Too

ASCO 2020 – Lung Cancer

For oncologists and others who advocate for smoking cessation, it is important to know whether recent quitters who are diagnosed with lung cancer can achieve a survival benefit. Read More ›

Weekly Epirubicin as Second-Line Therapy for Malignant Pleural Mesothelioma

ASCO 2020 – Lung Cancer

Weekly epirubicin was evaluated as a potential “gentle” option for second-line chemotherapy in patients with malignant pleural mesothelioma after failure of first-line pemetrexed-based chemotherapy. Read More ›

Combination of Nivolumab, Ipilimumab, and Chemotherapy in Metastatic NSCLC

ASCO 2020 – Lung Cancer

Combining nivolumab plus ipilimumab with 2 cycles of chemotherapy may be effective in patients undergoing first-line treatment for metastatic non–small-cell lung cancer. Read More ›

American Society of Clinical Oncology (ASCO)

Page 12 of 33